Streetbeat News

Analyst Ratings

DNB

Needham analyst Kyle Peterson has reiterated a 'Buy' rating on Dun & Bradstreet Hldgs (NYSE:DNB) and maintained a price target of $18.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 10:27 am

GEHC

Wells Fargo analyst Larry Biegelsen has initiated coverage on GE HealthCare Techs (NASDAQ:GEHC) with an Overweight rating and a price target of $90.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 10:02 am

VSAT

JP Morgan analyst Philip Cusick has reinstated Viasat (NASDAQ:VSAT) with a Neutral rating and announced a $35 price target.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 9:59 am

CHK

JP Morgan analyst Zach Parham has downgraded Chesapeake Energy (NASDAQ:CHK) from Overweight to Neutral and lowered the price target from $97 to $96.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 9:57 am

MGY

Mizuho analyst Nitin Kumar has downgraded Magnolia Oil & Gas (NYSE:MGY) from Buy to Neutral.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 9:56 am

DINO

Mizuho analyst Nitin Kumar has downgraded HF Sinclair (NYSE:DINO) from Buy to Neutral.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 9:55 am

MPC

Mizuho analyst Nitin Kumar has downgraded Marathon Petroleum (NYSE:MPC) from Buy to Neutral.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 9:52 am

DEA

RBC Capital's analyst Michael Carroll has downgraded Easterly Government Props (NYSE:DEA) from Sector Perform to Underperform and lowered the price target from $15 to $13.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 9:51 am

ZYNE

Canaccord Genuity analyst Sumant Kulkarni has downgraded Zynerba Pharmaceuticals from Buy to Hold and lowered the price target from $10 to $1.11.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 9:50 am

AAPL

Evercore ISI analyst Amit Daryanani has expressed optimism about the upcoming redesign of the Apple Watch, stating that it will add significant value to the series. The new design, part of the Series X lineup, is expected to include a slimmer case, revamped band attachments, and blood-pressure monitoring technology. Daryanani, who has a bullish outlook on Apple with a $210 price target, believes the redesign will attract both existing users and those currently using competitor models.

Portfolio Pulse from Benzinga Neuro

August 16, 2023 | 9:49 am